BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...other therapies, in particular the amylin analogue AM833...
...issues. But strong Phase I data from the AM833/semaglutide combination...
...Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) AM833, NN9838 Novo...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...past the 20% reduction mark. The company is already testing the drug in combination with AM833...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...said. The first combination approach to read out with that sort of potential is Novo’s AM833...
...Phase I combination study is expected in 2H20. In an eight-week Phase I trial of AM833...
...translates to nearly 1% per week. Novo is also expecting a Phase II readout of AM833...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

...in 1H19. The five other obesity programs are all in Phase I: long-acting amylin analog AM833...
...based on the Byetta exenatide molecule, he said. In addition, he thinks high-dose Ozempic plus AM833...
BioCentury | Mar 25, 2017
Strategy

Mountain climbing

...of semaglutide named NN9536 leads the obesity pipeline. Phase I candidates include long-acting amylin analog AM833...
Items per page:
1 - 5 of 5